163 related articles for article (PubMed ID: 25366656)
1. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
Samoylova ML; Dodge JL; Mehta N; Yao FY; Roberts JP
Clin Transplant; 2015 Jan; 29(1):52-9. PubMed ID: 25366656
[TBL] [Abstract][Full Text] [Related]
2. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
3. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
4. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
5. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
6. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
8. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
Alver SK; Lorenz DJ; Marvin MR; Brock GN
Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
[TBL] [Abstract][Full Text] [Related]
9. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
[TBL] [Abstract][Full Text] [Related]
10. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
11. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
12. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma.
Battula N; Reichman TW; Amiri Y; Carmody IC; Galliano G; Seal J; Bugeaud E; Bohorquez H; Bruce D; Cohen A; Loss GE
Liver Transpl; 2017 Mar; 23(3):299-304. PubMed ID: 28026108
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.
Croome KP; Lee DD; Harnois D; Taner CB
PLoS One; 2017; 12(1):e0170673. PubMed ID: 28122003
[TBL] [Abstract][Full Text] [Related]
14. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
15. Time of Dropout From the Liver Transplant List in Patients With Hepatocellular Carcinoma: Clinical Behavior According to Tumor Characteristics and Severity of Liver Disease.
Salvalaggio PR; Felga GE; Guardia BD; Almeida MD; Pandullo FL; Matielo CE; Evangelista A; Curvelo L; Rocco RA; Alves JA; Meirelles RF; Filho SP; de Rezende MB; Pedroso PT; Diaz LG; Rusi MB; Viveiros MM; Neves DB
Transplant Proc; 2016 Sep; 48(7):2319-2322. PubMed ID: 27742288
[TBL] [Abstract][Full Text] [Related]
16. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.
Samoylova ML; Dodge JL; Yao FY; Roberts JP
Liver Transpl; 2014 Aug; 20(8):937-44. PubMed ID: 24797145
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
[TBL] [Abstract][Full Text] [Related]
20. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
